The DOI matches its OpenAlex record.
Determinants of Vertebral Mineral Density in Patients Receiving Long-term Glucocorticoid Therapy
Abstract
This study addresses the impact of clinical and biochemical factors on the bone density of patients receiving glucocorticoid therapy. Vertebral mineral density was measured by quantitative computed tomography in 35 patients aged 17 to 77 years who had received therapeutic glucocorticoid drugs for 0.1 to 22 years. The mean (+/- SEM) vertebral mineral density z score in the subjects was -1.7 +/- 0.2. z score was unrelated to underlying diagnosis, sex, or age but was significantly related to the duration of previous steroid therapy (r = -.38) and to the total cumulative glucocorticoid dose (r = -.50). The rate of change of bone density in 16 of these subjects followed up over a period of 12 months was -8.9% and was significantly greater in subjects taking more than 12.5 mg of prednisone per day. Bone loss was not influenced by sex, age, duration of previous steroid treatment, or diagnosis and was not predictable from biochemical measures of calcium metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
“[104] reported that younger people are more susceptible than the elderly, but other studies reported an absence of age effect [35,61,66,101].”
Glucocorticoid Therapy for Immune-Mediated Diseases: Basic and Clinical Correlates
Boumpas, D. T., Chrousos, G. P., Wilder, R. L., Cupps, T. R., & Balow, J. E. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-12-199312150-00007 · Cited by 778
Cohen, S., Levy, R. M., Keller, M., Boling, E., Emkey, R. D., Greenwald, M., Zizic, T. M., Wallach, S., Sewell, K. L., Lukert, B. P., et al. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199911)42:11<2309::aid-anr8>3.0.co;2-k · Cited by 613
Da Silva, J. A. P., Jacobs, J. W. G., Kirwan, J. R., Boers, M., Saag, K. G., Inês, L. B. S., de Koning, E. J. P., Buttgereit, F., Cutolo, M., Capell, H., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.038638 · Cited by 522
Gut, inflammation and osteoporosis: Basic and clinical concepts
Tilg, H., Moschen, A. R., Kaser, A., Pines, A., & Dotan, I. (2008) · Gut · doi:10.1136/gut.2006.117382 · Cited by 292
“Patients treated with corticosteroids therefore have an increased risk for osteoporosis and associated fractures.(13) 14 More importantly, risk for osteoporosis increases early on, hence the worst effect on bone mineral density is within the first few months of treatment.”
BackgroundPrevention and treatment of systemic glucocorticoid side effects
Moghadam‐Kia, S., & Werth, V. P. (2010) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2009.04322.x · Cited by 286
McEVOY, C. E., ENSRUD, K. E., BENDER, E., GENANT, H. K., YU, W., GRIFFITH, J. M., & NIEWOEHNER, D. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.3.9703080 · Cited by 285
Glucocorticoid osteoporosis--mechanisms and management
Reid, I. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1370209 · Cited by 278
Self-citationBone safety of low-dose glucocorticoids in rheumatic diseases
Saag, K. G. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12446 · Cited by 15
Goemaere, S., Liberman, U. A., Adachi, J. D., Hawkins, F., Lane, N., Saag, K. G., Schnitzer, T., Kaufman, J. M., Malice, M. P., Carofano, W., et al. (2003) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000073586.28977.31 · Cited by 7
Metadata
- Authors
- Reid, I. R.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association
- Published
- 1990-12-01
- Volume
- 150
- Issue
- 12
- Pages
- 2545-2545
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2119243846
- Cited by
- 184
- References
- 0
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.